RxDoctor Payments DataLook up a doctor →

Vicky Makker, MD

Hematology & Oncology · New York, NYNPI 1972769800

Payments from drug & device makers

$27,115,100in general payments, 2019–2025

Across 4,639 payments — averaging $5845.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$14.7M
  • Eisai Inc.$8.8M
  • AstraZeneca$2.7M
  • Karyopharm Therapeutics Inc.$412K
  • Clovis Oncology, Inc.$379K
  • Takeda Pharmaceuticals U.S.A., Inc.$85K
  • plus $78K from 5 others

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck336$14,681,531
Eisai Inc.4,165$8,824,675
AstraZeneca19$2,654,401
Karyopharm Therapeutics Inc.83$411,982
Clovis Oncology, Inc.11$378,942
Takeda Pharmaceuticals U.S.A., Inc.17$85,226
Eli Lilly1$60,527
Organon2$17,378
Astrazeneca UK Limited3$403
Biontech SE1$19
GSK1$16

How this compares

$27,115,100 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York

Medicare billing

Part B allowed, 2024
$62,014
Medicare patients
137
Services billed
525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →